Differentiated injectables are the need of the hour.
We want to take the world from pain to pain-free parenterals through dedicated work on creating innovations. Emal the first in the world injectable medicine against critical malaria, Etojet – the world’s first painless Etrocoxib injection and a first of it’s kind injectable Diclofenac Sodium for pain relief, are all a result of the pursuit of ideas taken to their full potential. Our aim is to make disease management easier and painless for both patients and healthcare professionals.
Platform technology driven by crucial focus areas
Themis Platform Technology driven by crucial focus areas.
We develop injectables through our platform technology. The key focus areas are
Suspension to clear solution with ease of handling and reducing time for preparation
Lyophilized powder to ready to infuse solutions with extended drug stability
Oily injectables to oil free formulations to reduce pain on administration
Innovations in differentiated injectables and beyond
We are well-known for both formulations and API’s. Area of our innovation and research includes
Health and Nutrition
A journey of over 45 years
Founded in 1969 by the pioneering efforts of Dr. Shantibhai D. Patel, Themis became even stronger with a joint venture with Gedeon Richter Ltd., Hungary. The result is 4 state-of-the-art manufacturing facilities in India, a nation-wide stockist network of over 4000 stockists and operations in over 64 countries. Along the way we have forged partnerships for development and marketing with many industry leaders, working symbiotically towards a healthier future. We are a business yes, but we are also on the forefront of alleviating pain and enhancing human life. And this is what motivates us to keep going.
We want to take the world from pain to pain-free parentals through pain free work on dedicated innovations. Emal – the first in the world injectable against critical malaria, Etojet – the worlds first painless Etrocoxib injection and a first of its kinds injectable.
Diclofenac sodium for pain relief, are all a result of pursuit of ideas taken to their full potential. Our aim is to make disease management easier and painless for both patients and healthcare professionals.
- lntimation under regulation 39(3) of Securities and Exchanae Board of India (Listinq Obligations and Disclosure Requirements) Requlation, 2015 [“SEBI (LODR) Regulations, 2015″] 07/Mar/2019
- Outcome of Board Meeting – 08 Feb 2019 08/Feb/2019
- Intimation of Board Meeting – 08 Feb 2019 25/Jan/2019
- Postal Ballot Result 31-Dec-2018 31/Dec/2018
- Postal Ballot Notice & Form 29/Nov/2018
11/12, Udyog Nagar,
S. V. Road, Goregaon (W),